-transparent.png){kind=logo}
Factor VIII inhibitors in mild haemophilia are uncommon and the management of such patients is controversial. The development of a persistently high responding F VIII inhibitor in a mild haemophiliac is reported and the behaviour of the inhibitor discussed in the context of the various therapeutic regimes employed for symptomatic management. When inhibitor titres were low, endogenous F VIII stimulation, by DDAVP, was less immunogenic than the administration of exogenous F VIII concentrates. This inhibitor displayed characteristics of an autoantibody, and was characterised as an immunoglobulin of IgG subtype.
Related Publications
P J Kesteven, and
L J Holland, and
A S Lawrie, and
G F Savidge
February 1985,
Thrombosis and haemostasis,
P J Kesteven, and
L J Holland, and
A S Lawrie, and
G F Savidge
April 1986,
British journal of haematology,
P J Kesteven, and
L J Holland, and
A S Lawrie, and
G F Savidge
December 1975,
Haematologica,
P J Kesteven, and
L J Holland, and
A S Lawrie, and
G F Savidge
March 2001,
Haemophilia : the official journal of the World Federation of Hemophilia,
P J Kesteven, and
L J Holland, and
A S Lawrie, and
G F Savidge
January 2015,
Medicina,
P J Kesteven, and
L J Holland, and
A S Lawrie, and
G F Savidge
May 2014,
Haemophilia : the official journal of the World Federation of Hemophilia,
P J Kesteven, and
L J Holland, and
A S Lawrie, and
G F Savidge
October 1985,
British journal of haematology,
P J Kesteven, and
L J Holland, and
A S Lawrie, and
G F Savidge
September 1969,
British journal of haematology,
P J Kesteven, and
L J Holland, and
A S Lawrie, and
G F Savidge
May 2012,
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP,
P J Kesteven, and
L J Holland, and
A S Lawrie, and
G F Savidge
July 1998,
Haemophilia : the official journal of the World Federation of Hemophilia,
